Yibai Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company at a loss of 80.34 million yuan, an increase in loss of 60.44 million yuan compared with the same period last year. The company's total operating revenue was 689 million yuan, down 30.58% year-on-year; net cash inflow from operating activities was 64.14 million yuan, down 62.39% year-on-year. The company's latest asset-liability ratio was 32.90%, gross margin was 57.67%, ROE was -3.81%, and diluted earnings per share was -0.10 yuan.
Guizhou Yibai Pharmaceutical Co LtdNet loss widened and revenue fell sharply in interim report.
